Healthcare

Firebrick Pharma Limited (ASX:FRE), an Australian pharmaceutical company developing povidone-iodine products for respiratory health, continues to build international distribution for its Nasodine range while progressing intellectual-property protection. At the time of writing this article on 19 October 2026, the shares were quoted at AUD …

Mesoblast develops medicines derived from donor-sourced mesenchymal lineage cells, designed to address inflammatory and immune-mediated conditions. Its first US-approved product, Ryoncil (remestemcel-L-rknd), treats steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. The company also studies remestemcel-L for additional inflammatory indications …

The group operates through three complementary activities. Its medical imaging software business provides quantitative image-analysis tools used in healthcare and research. Its clinical research organisation undertakes services connected with pharmaceutical studies, while the TrialsWest network supports the delivery of clinical trials through investigator sites. …

• Its one-year share-price change stood at +8.02%, contrasting with the latest daily move.

• Its one-year share-price change stood at -15.39%, contrasting with the latest daily move.

• Its one-year share-price change stood at -91.72%, contrasting with the latest daily move.

• Its one-year share-price change stood at -55.56%, contrasting with the latest daily move.